Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Cigna

Federal regulators probe Cigna’s pharmacy benefit manager, CVS Caremark, and others. What are they investigating?

Express Scripts, the pharmacy benefit manager that Cigna Corp. bought in 2018, is being investigated by the Federal Trade Commission for what regulators claim is influence over drug prices wielded by pharmacy benefit managers and transparent business practices.

Tribune News Service

Analyzing Cigna's Short Interest

Cigna's (NYSE:CI) short percent of float has fallen 6.8% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 0.96% of all regular shares that are available for trading.

Benzinga

What Are Whales Doing With Cigna

Someone with a lot of money to spend has taken a bullish stance on Cigna (NYSE:CI). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

When medical test costs suddenly change

Preventive care should be free under the ACA. An investigation found it doesn't always work that way in practice

Salon

Cancer screenings like colonoscopies are supposed to be free. Hers cost $2,185

Preventive care, like screening colonoscopies, is supposed to be free of charge to patients under the Affordable Care Act. But some hospitals haven't gotten the memo.

WEKU

$1000 Invested In Cigna 10 Years Ago Would Be Worth This Much

Cigna (NYSE:CI) has outperformed the market over the past 10 years by 7.87% on an annualized basis producing an average annual return of 19.99%. Currently, Cigna has a market capitalization of $86.15 billion.

Benzinga

14 Analysts Have This to Say About Cigna

Cigna (NYSE:CI) has observed the following analyst ratings within the last quarter:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2022

Upgrades

Benzinga

Supreme Court leak prompts investors to press companies on abortion

WASHINGTON — Activist shareholders, seeking to galvanize support following a leaked Supreme Court draft opinion indicating that justices are poised to overturn Roe v. Wade, are pressing companies to explicitly explain how they will support their workers’ access to abortion and reproductive health services.

Tribune News Service

SCOTUS leak prompts investors to press companies on abortion - Roll Call

Activist shareholders are pressuring companies on access to abortion after a leaked draft Supreme Court opinion.

Roll Call

Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2022

Upgrades

Benzinga

Eli Lilly, Albemarle Lead Five Ways To Play A Stock Market Rally

Eli Lilly and Albemarle lead five stocks that have shown resilience amid the sell-off and may be poised to lead the way forward.

Investors Business Daily

Dow Jones Futures Jump; TWTR Stock Crashes, Pares Losses On Elon Musk's Twitter Deal Tweets

Futures are rising. Will this bounce stick? TWTR stock initially crashed as Tesla CEO Elon Musk put the Twitter deal "on hold."

Investors Business Daily

10 Analysts Have This to Say About Cigna

Analysts have provided the following ratings for Cigna (NYSE:CI) within the last quarter:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022

Upgrades

Benzinga

Cigna's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Cigna (NYSE:CI) posted Q1 earnings of $1.20 billion, an increase from Q4 of 5.74%. Sales dropped to $44.11 billion, a 3.43% decrease between quarters.

Investors Business Daily

Cigna Stock Clears Key Benchmark, Hitting 90-Plus RS Rating

Cigna sees its Relative Strength Rating move into the elite 90-plus level.

Benzinga

Peering Into Cigna's Recent Short Interest

Cigna's (NYSE:CI) short percent of float has fallen 15.67% since its last report. The company recently reported that it has 3.53 million shares sold short, which is 1.13% of all regular shares that are available for trading.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap: Cigna Q1 Earnings

Cigna (NYSE:CI) reported its Q1 earnings results on Friday, May 6, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings Cigna beat estimated earnings by 16.02%, reporting an EPS of $6.01 versus an estimate of $5.18.

Benzinga

Here's How Much You Would Have Made Owning Cigna Stock In The Last 15 Years

Cigna (NYSE:CI) has outperformed the market over the past 15 years by 4.13% on an annualized basis producing an average annual return of 11.01%. Currently, Cigna has a market capitalization of $83.55 billion.

Benzinga

Cigna Q1 Earnings Beat Expectations, Lifts FY22 Guidance

Cigna Corp (NYSE:CI) reports Q1 total revenues of $44.12 billion, +7.6% Y/Y, ahead of the consensus of $43.41 billion. Cigna brought in $1.18 billion in earnings, up from $1.16 billion a year ago. Q1 adjusted EPS reached $6.01 compared with $4.73 a year ago, beating the consensus of $5.18. By the end of…

Benzinga

Cigna: Q1 Earnings Insights

Benzinga

Cigna's Earnings Outlook

Cigna (NYSE:CI) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Cigna will report an earnings per share (EPS) of $5.18.

Benzinga

Cigna Q1 2022 Earnings Conference Call On May 6, 2022 At 08:30 AM ET

Cigna (NYSE:CI) will host a conference call at 08:30 AM ET on May 6, 2022, to discuss Q1 2022 earnings results. How to Attend Cigna (CI) Conference Call Follow this link to access the live webcast.

The Independent UK

Can billionaire celebrity Mark Cuban fix America’s broken health system?

The celebrity investor has teamed up with a soft-spoken radiologist to tackle the USA’s healthcare crisis – and he has drug industry middlemen squarely in his sights, reports Io Dodds

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.